Skip to main
LNTH

Lantheus Holdings (LNTH) Stock Forecast & Price Target

Lantheus Holdings (LNTH) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 14%
Buy 43%
Hold 43%
Sell 0%
Strong Sell 0%

Bulls say

Lantheus Holdings is a radiopharmaceutical-focused company that produces and markets products for cancer and disease detection and monitoring. The company's recent FDA approvals for PYLARIFY TruVu and its tentative approval for PNT2003 demonstrate its strong product pipeline and potential for growth. Additionally, the company's focus on strategic partnerships and expansion into international markets provide further opportunities for revenue growth. However, there are also risks related to regulation and reimbursement, as well as potential disruptions to the company's manufacturing and distribution networks. As a financial analyst, the positive outlook for this stock is based on the potential for continued revenue growth and a focus on innovation and expansion into new markets, which could drive shareholder value in the long term.

Bears say

Lantheus Holdings is currently facing challenges due to pricing declines and strong competition in the oncology market, which is causing a decline in revenue. Additionally, while the company has a promising pipeline in the Alzheimer's diagnostic market, it may still be a few years before they see significant contribution from these products. With limited short-term catalysts and a negative outlook for the oncology market, the stock may continue to underperform in the near future.

Lantheus Holdings (LNTH) has been analyzed by 7 analysts, with a consensus rating of Buy. 14% of analysts recommend a Strong Buy, 43% recommend Buy, 43% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lantheus Holdings (LNTH) Forecast

Analysts have given Lantheus Holdings (LNTH) a Buy based on their latest research and market trends.

According to 7 analysts, Lantheus Holdings (LNTH) has a Buy consensus rating as of Aug 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $102, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $102, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lantheus Holdings (LNTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.